Biodesix Publishes Largest Lung Nodule Biomarker Validation Study Supporting Earlier Cancer Detection
核心洞察
Biodesix (搜索) published the largest lung nodule biomarker clinical validation study ever conducted, analyzing over 1,100 patients with noncalcified lung nodules ranging from 4-30 mm in size.
The Nodify CDT (搜索)® test demonstrated consistently high specificity of 91-97% across different nodule sizes and patient populations, indicating low false positive rates for lung cancer detection.
The validation study included data from four distinct clinical studies across 48 clinical practices in the US, including real-world clinical care settings.
Biodesix (搜索), Inc. (Nasdaq: BDSX) announced the publication of the largest lung nodule biomarker clinical validation study ever conducted, strengthening the clinical foundation for its Nodify CDT (搜索)® test as a decision-support tool in early lung cancer detection. The study addresses a significant unmet need in managing the millions of lung nodules detected annually in the United States.
Study Design and Scope
The retrospective pooled analysis, published in Future Oncology in February 2026, examined over 1,100 patients with noncalcified lung nodules ranging in size from 4-30 mm who had Nodify CDT (搜索) test results. The study, titled "Validation of a blood-based autoantibody test to assess lung cancer risk in 4-30mm pulmonary nodules: a retrospective pooled analysis of four cohort studies," represents the most comprehensive validation of a lung nodule biomarker test to date.
The analysis included data from four distinct clinical studies with patients enrolled from 48 clinical practices across the United States, including the CLARIFY study (NCT06728319) where patients received the Nodify CDT (搜索) test as part of real-world clinical care.
Clinical Performance Results
The Nodify CDT (搜索) test demonstrated consistently high specificity ranging from 91-97%, indicating low false positive rates regardless of nodule size or baseline patient risk factors. This performance consistency was maintained across all four clinical studies and diverse practice settings, substantiating the test's clinical applicability in real-world scenarios.
"The data shows that the Nodify CDT (搜索) test detected lung cancer with minimal false positives for nodules 4-30 mm in size," confirmed Dr. Luke Yuhico, Pulmonologist at Fort Walton-Destin Hospital (搜索), FL. "In my own practice, I have observed that using Nodify Lung testing, in conjunction with the information on the patient's scan, significantly assists in my team's decision-making as we strive to meaningfully impact patient outcomes by finding cancer much earlier, even in very small nodules."
Clinical Context and Unmet Need
The clinical challenge in lung nodule management stems from the fact that most small nodules are benign, requiring clinicians to balance "watch and wait" approaches with imaging surveillance against expedited intervention based on limited CT scan insights. Dr. James Jett, Co-Chief Medical Officer at Biodesix (搜索) and former Pulmonologist at Mayo Clinic, emphasized the urgency of this clinical need.
"A recent study reported in the journal THORAX (by The SUMMIT consortium) observed that over 40% of malignant pulmonary nodules progressed in tumor size between the time of first detection and the time of definitive treatment," Dr. Jett noted. "This highlights a clinician's need for more helpful decision-support tools to expedite diagnosis and treatment, such as Nodify Lung® Nodule Risk Assessment."
Commercial and Clinical Implications
Scott Hutton, CEO & President of Biodesix (搜索), stated that the comprehensive validation study supports continued commercial expansion of the Nodify CDT (搜索) test and reinforces its clinical utility in addressing substantial market opportunities and system-wide gaps in lung nodule management. The demonstrated consistency across real-world practice settings strengthens the company's position with healthcare providers, payers, and clinical guideline committees.
The Nodify CDT (搜索) test is currently available for clinical use in patients with 4-30 mm lung nodules. The blood-based autoantibody test is part of Biodesix (搜索)'s broader diagnostic portfolio, which includes the Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance systems designed to support clinical decisions and improve outcomes for patients with lung disease.